Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15859333 | 0.85 | FFAR3 (0.74) | FFAR3KDM4E | |
| SCHEMBL5067774 | 0.84 | FFAR3 (1.00) | FFAR3KDM4E | |
| SCHEMBL5202041 | 0.82 | FFAR3 (0.76) | FFAR3KDM4E | |
| SCHEMBL15866593 | 0.81 | FFAR3 (0.84) | FFAR3KDM4E | |
| SCHEMBL5064866 | 0.81 | FFAR3 (0.76) | FFAR3KDM4E | |
| SCHEMBL5067838 | 0.80 | FFAR3 (0.82) | FFAR3KDM4E | |
| SCHEMBL3263109 | 0.79 | FFAR3 (0.84) | FFAR3KDM4E | |
| SCHEMBL5064697 | 0.79 | FFAR3 (0.79) | FFAR3KDM4E | |
| SCHEMBL2990862 | 0.78 | KDM4E (0.66) | FFAR3KDM4E | |
| SCHEMBL3265079 | 0.78 | FFAR3 (0.74) | FFAR3KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1812080-B1 | GPR41 AND MODULATORS THEREOF FOR THE TREATMENT OF INSULIN-RELATED DISORDERS | ARENA PHARM INC (US) | 2014-07-09 | — | — | EP | claimed |
| US-20080312277-A1 | Gpr41 and Modulators Thereof for the Treatment of Insulin-Related Disorders | ARENA PHARMACEUTICALS, INC. | 2008-12-18 | — | — | US | claimed |
| EP-1812080-B1 | GPR41 AND MODULATORS THEREOF FOR THE TREATMENT OF INSULIN-RELATED DISORDERS | ARENA PHARM INC (US) | 2014-07-09 | — | — | EP | disclosed |
| EP-1812080-B1 | GPR41 AND MODULATORS THEREOF FOR THE TREATMENT OF INSULIN-RELATED DISORDERS | ARENA PHARM INC (US) | 2014-07-09 | — | — | EP | disclosed |
| US-20080312277-A1 | Gpr41 and Modulators Thereof for the Treatment of Insulin-Related Disorders | ARENA PHARMACEUTICALS, INC. | 2008-12-18 | — | — | US | disclosed |
| US-20080312277-A1 | Gpr41 and Modulators Thereof for the Treatment of Insulin-Related Disorders | ARENA PHARMACEUTICALS, INC. | 2008-12-18 | — | — | US | disclosed |
| US-20080312277-A1 | Gpr41 and Modulators Thereof for the Treatment of Insulin-Related Disorders | ARENA PHARMACEUTICALS, INC. | 2008-12-18 | — | — | US | disclosed |
| EP-1812080-A2 | GPR41 AND MODULATORS THEREOF FOR THE TREATMENT OF INSULIN-RELATED DISORDERS | Arena Pharmaceuticals, Inc. (US) | 2007-08-01 | — | — | EP | disclosed |
| WO-2006052566-A2 | GPR41 AND MODULATORS THEREOF FOR THE TREATMENT OF INSULIN-RELATED DISORDERS | ARENA PHARMACEUTICALS, INC. (US) | 2006-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312277-A1 | Gpr41 and Modulators Thereof for the Treatment of Insulin-Related Disorders | GPR119, GPR4, GLP1R | FFAR3 29/4885KDM4E 3458/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.